Synektik

Synektik Capital Expenditures

The Capital Expenditures (CapEx) of Synektik (SNT.WA) as of Oct 31, 2026 is -18.14 M PLN. In the previous year, Capital Expenditures (CapEx) was -44.87 M PLN — a change of -59.57% (higher).

Capital Expenditures

-18.14 MPLN

YoY

-59.57%

Last updated:

Capital Expenditures (CapEx) of Synektik is 2025 -18.14 M PLN. Capital Expenditures (CapEx) of Synektik was 2024 -44.87 M PLN. It decreases by -59.57% higher compared to the previous year.

The Synektik Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-2.37 M PLN
Jan 1, 2019
-5.51 M PLN
Jan 1, 2020
-5.11 M PLN
Jan 1, 2021
-3.43 M PLN
Jan 1, 2022
-10.22 M PLN
Jan 1, 2023
-8.29 M PLN
Jan 1, 2024
-44.87 M PLN
Jan 1, 2025
-18.14 M PLN
The Synektik Capital Expenditures history
YEARCapital ExpendituresYoY
-18.14 MPLN-59.57%
-44.87 MPLN+440.98%
-8.29 MPLN-18.86%
-10.22 MPLN+197.99%
-3.43 MPLN-32.93%
-5.11 MPLN-7.24%
-5.51 MPLN+132.26%
-2.37 MPLN-64.52%
-6.69 MPLN-4.16%
-6.98 MPLN-34.02%
-10.58 MPLN-30.02%
-15.12 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Synektik Stock analysis

What does Synektik do? Synektik SA generates revenue through its PACS software, which enables diagnostic imaging laboratories to operate efficiently. The company also sells medical equipment and provides services through its imaging equipment services center. Synektik SA partners with Siemens and holds a 100% stake in Miedzynarodowe Centra Medyczne Inwestycje Sp z o o, which it acquired by raising its stake on November 28, 2013. The firm's research laboratory conducts acceptance and specialist tests on X-ray equipment, contributing to its service offerings. The primary buyers of Synektik SA's products include diagnostic imaging laboratories that require PACS software for their operations. Medical equipment is sold to healthcare facilities, while the research laboratory services are utilized by entities needing X-ray equipment testing. The company's partnership with Siemens supports its medical equipment sales and services. Synektik SA's revenue streams are derived from software licensing, medical equipment sales, and specialized testing services. The company's focus on diagnostic imaging solutions and its ownership of Miedzynarodowe Centra Medyczne Inwestycje Sp z o o position it within the medical technology sector, targeting healthcare providers and imaging laboratories. Synektik is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Synektik stock

Capital Expenditures (CapEx) of Synektik is -18.14 M PLN in 2025.

Capital Expenditures (CapEx) of Synektik changed from -44.87 M PLN to -18.14 M PLN, representing a -59.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Synektik since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Synektik historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Synektik

All Key Metrics — Synektik